Patents by Inventor Iwao Ohizumi

Iwao Ohizumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY AGAINST SECRETED N-TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3
    Publication number: 20200181248
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 11, 2020
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki ABURATANI, Yutaka MIDORIKAWA, Kiyotaka NAKANO, Iwao OHIZUMI, Yukio ITO, Susumu TOKITA
  • Antibody Against Secreted N-Terminal Peptide of GPC3 Present in Blood or C-Terminal Peptide of GPC3
    Publication number: 20170233462
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: October 7, 2016
    Publication date: August 17, 2017
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki ABURATANI, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Method for diagnosing cancer by detecting GPC3
    Patent number: 9513292
    Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 6, 2016
    Assignee: Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • METHOD FOR DIAGNOSING CANCER BY DETECTING GPC3
    Publication number: 20150132782
    Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
    Type: Application
    Filed: December 22, 2014
    Publication date: May 14, 2015
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3
    Publication number: 20100183595
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: September 11, 2009
    Publication date: July 22, 2010
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Cell growth inhibitor containing anti-PepT antibody
    Patent number: 7666998
    Abstract: The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 23, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Iwao Ohizumi
  • Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3
    Publication number: 20090060907
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: June 1, 2007
    Publication date: March 5, 2009
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Tumor vessel endothelial cell-binding monoclonal antibodies
    Patent number: 7189824
    Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody, pharmaceutical agents comprising the monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of the monoclonal antibody and another conjugating molecule.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: March 13, 2007
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
  • Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3
    Publication number: 20060188510
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: April 28, 2006
    Publication date: August 24, 2006
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Antibody against n-terminal peptide or c-terminal peptide of gpc3 solubilized in blood
    Publication number: 20060167232
    Abstract: Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same, which can disrupt cells, in particular cancer cells.
    Type: Application
    Filed: September 4, 2003
    Publication date: July 27, 2006
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Cell growth regulator
    Publication number: 20060100280
    Abstract: The present inventors examined cell growth of human colon cancer cell lines and breast cancer cell lines using L-2-phenylglycine, which is considered to be an amino acid transporter ATB0,+ inhibitor, as a test substance to reveal a concentration-dependent cell growth inhibitory effect. This result shows that inhibition of ATB0,+ activity may suppress cell growth. Suppression of the amino acid transporter ATB0,+ activity may be an important index in developing growth inhibitors for cancer cells and such.
    Type: Application
    Filed: October 10, 2003
    Publication date: May 11, 2006
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takahiro Hatanaka, Iwao Ohizumi, Jun-ichi Nezu
  • Method for diagnosing cancer by detecting gpc3
    Publication number: 20060014223
    Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
    Type: Application
    Filed: September 4, 2003
    Publication date: January 19, 2006
    Applicant: Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Cell proliferation inhibitor containing anti-pept antibody
    Publication number: 20050281825
    Abstract: The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.
    Type: Application
    Filed: December 4, 2002
    Publication date: December 22, 2005
    Inventors: Tatsuhiko Kodama, Takao Hamakubo, Ryoichi Saitoh, Iwao Ohizumi
  • Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
    Patent number: 6440733
    Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing said monoclonal antibody, pharmaceutical agents comprising said monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of said monoclonal antibody and another conjugating molecule.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 27, 2002
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
  • Altering the properties of cells or of particles with menbranes derived from cells by means of lipid-modified proteinaceous molecules
    Publication number: 20020081305
    Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing said monoclonal antibody, pharmaceutical agents comprising said monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of said monoclonal antibody and another conjugating molecule.
    Type: Application
    Filed: November 8, 2001
    Publication date: June 27, 2002
    Inventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi